0.468

1.47% -0.007

Estrella Immunopharma Inc (ESLA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.475

Offen:

$0.461

24-Stunden-Volumen:

14,485

Relative Volume:

0.37

Marktkapitalisierung:

$20.36M

Einnahmen:

Nettoeinkommen (Verlust:

$-13.25M

KGV:

-1.3247

EPS:

-0.3533

Netto-Cashflow:

$-8.02M

1W Leistung:

-2.70%

1M Leistung:

-32.17%

6M Leistung:

-55.43%

1J Leistung:

-64.55%

1-Tages-Spanne:

$0.4602

$0.5055

1-Wochen-Bereich:

$0.4313

$0.5055

52-Wochen-Spanne:

$0.4313

$3.15

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Firmenname

Estrella Immunopharma Inc

Sektor

Healthcare (1064)

Branche

Biotechnology (595)

Telefon

(510) 318-9098

Adresse

5858 HORTON STREET, SUITE 370, EMERYVILLE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-05-13

Neueste SEC-Einreichungen

ESLA's Discussions on Twitter

Compare ESLA vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ESLA Estrella Immunopharma Inc	0.468	20.92M	0	-13.25M	-8.02M	-0.3533
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten

Oct 01, 2026

Estrella’s EB103 Lymphoma Trial Advances, Keeping High-Risk Cell Therapy Hopes Alive - TipRanks

Oct 01, 2026

Sep 20, 2026

Estrella Immunopharma Warrant (ESLAW) Trades Flat at $0.07 as Range Holds TightAI Trade Signals - dars.gov.et

Sep 20, 2026

Sep 08, 2026

Estrella Immunopharma Faces Nasdaq Listing Compliance Challenge - TipRanks

Sep 08, 2026

Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Sep 08, 2026

Aug 26, 2026

Estrella (ESLA) Earnings Reading: EPS Falls Short of Its Estimate in the Current Update; Market Response: The Stock Records a 1.20% Increase in the Latest SessionRevenue Growth Outlook - dars.gov.et

Aug 26, 2026

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial - Yahoo Finance

Aug 26, 2026

Aug 21, 2026

Estrella Immunopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks

Aug 21, 2026

Aug 20, 2026

ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half - GuruFocus

Aug 20, 2026

Aug 18, 2026

Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - Kalkine

Aug 18, 2026

Aug 16, 2026

Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center StageLong Short Pair - vinanet.vn

Aug 16, 2026

Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView

Aug 16, 2026

Aug 15, 2026

Estrella Immunopharma (ESLA) Holds at $0.72 as Support Firms in Quiet Micro-Cap SessionIchimoku TK Cross - vinanet.vn

Aug 15, 2026

ESLAW Warrants Hold Flat at $0.07 as Support and Resistance AlignInstitutional Buy Signals - vinanet.vn

Aug 15, 2026

Aug 14, 2026

ESLAW Warrant Holds at $0.07 as Estrella Immunopharma Trades FlatSystematic Flow - vinanet.vn

Aug 14, 2026

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary - TradingView

Aug 13, 2026

Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com

Aug 13, 2026

Aug 11, 2026

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace

Aug 11, 2026